G. Walsh

Publications110
h-index27
Citations6,018
Highly Influential Citations244
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • B. Yao
  • 337 Publications • 7,960 Citations
  • Huiying Luo
  • 237 Publications • 5,203 Citations
  • D. Prazeres
  • 275 Publications • 6,223 Citations
  • P. Shi
  • 153 Publications • 4,334 Citations
  • Publications
  • Influence
Biopharmaceutical benchmarks 2010
  • G. Walsh
  • Business, Medicine
    Nature Biotechnology
  • 1 September 2010
Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic…
Biopharmaceutical benchmarks 2014
  • G. Walsh
  • Business, Medicine
    Nature Biotechnology
  • 9 October 2014
Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a…
Post-translational modifications in the context of therapeutic proteins
TLDR
A better understanding of the relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation.
Biopharmaceutical benchmarks
  • G. Walsh
  • Medicine
    Nature Biotechnology
  • 2000
Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.
Biopharmaceutical benchmarks 2018
  • G. Walsh
  • Medicine, Business
    Nature Biotechnology
  • 1 December 2018
Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand…
Purification and characterization of extracellular phytase from Aspergillus niger ATCC 9142.
TLDR
Initial characterisation of the purified enzyme suggested that it could be a potential candidate for use as an animal feed supplement because of its higher thermostability and ability to hydrolyse non-phytate-based substrates.
Post-translational modifications of protein biopharmaceuticals.
  • G. Walsh
  • Computer Science, Medicine
    Drug discovery today
  • 15 April 2009
TLDR
This review considers the PTMs most often associated with therapeutic proteins and focuses upon more recent advances in engineering PTMs with the aim of improving the application-relevant functional characteristics of these drugs.
Proteins: Biochemistry and Biotechnology
TLDR
This chapter discusses the purification and characterization of therapeutic proteins, as well as industrial enzymes, of blood products and vaccines, and the role of proteases in this process.
Biopharmaceutical benchmarks 2006
  • G. Walsh
  • Engineering, Medicine
    Nature Biotechnology
  • 1 July 2006
The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.
Identification and characterization of a phytase of potential commercial interest.
TLDR
A phytase produced by Rhizopus oligosporus ATCC 22959 is significantly more thermostable at 80 degrees C and retains a significantly greater proportion of maximal activity at physiological temperatures than do two commercial phytases tested for comparative purposes.
...
1
2
3
4
5
...